Oncology · Medical Literature
Long-term outcomes and exploratory analysis from a randomized phase 3 trial of radiation dose escalation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Abstract
The optimal radiation dose for definitive chemoradiotherapy in locally advanced unresectable esophageal squamous cell carcinoma (ESCC) remains controversial, particularly whether dose escalation can overcome treatment resistance. We previously reported that escalation to 60 Gy increased radiation-related toxicity without improving short-term locoregional control versus 50 Gy. Here, we present the long-term outcomes and exploratory analyses of this randomized phase 3 trial. Between 2013 and 2017, 324 patients with stage IIA-IVA ESCC were randomly assigned 1:1 to receive 60 Gy or 50 Gy of conventionally fractionated radiotherapy with concurrent chemotherapy. Pretreatment biopsy specimens were analyzed using NanoString GeoMx digital spatial profiling for spatial transcriptomic and proteomic characterization. The full analysis set included 319 patients (60 Gy, n = 160; 50 Gy, n = 159). After a median follow-up of 99.5 months, no significant differences were observed in locoregional progression-free survival between the 60 Gy and 50 Gy groups, with 5- and 8-year rates of 41.8% and 32.7% versus 43.3% and 36.3%, respectively (HR 1.06, 95% CI 0.80-1.39, p = 0.70). Overall survival, progression-free survival, distant metastasis-free survival, and failure patterns were also comparable between groups. Spatial multi-omics analyses identified distinct baseline tumor microenvironment states associated with outcome. Long survivors showed an immune-activated profile with higher interferon and HLA signaling, and increased CD8+ T cell infiltration, whereas early progressors showed an immunosuppressive stromal profile suggestive of intrinsic resistance to definitive chemoradiotherapy. These findings support 50 Gy as an appropriate standard radiation dose for unselected patients with locally advanced ESCC treated with definitive chemoradiotherapy and do not support routine escalation to 60 Gy. Baseline spatial tumor microenvironment features may help identify resistance-associated states and provide biological context for divergent clinical outcomes.
Clinical relevance
In patients with locally advanced unresectable esophageal squamous cell carcinoma (ESCC) receiving definitive concurrent chemoradiotherapy with IMRT, does dose escalation to 60 Gy improve long-term locoregional progression-free survival, overall survival, and progression-free survival compared with 50 Gy? __SNAPSHOT__ {"studyDesign":"Randomized phase 3 trial (long-term follow-up and exploratory analysis of a previously reported trial; NCT01937208); multicenter","setting":"Multiple centers; China (inferred from trial characteristics and authorship); academic radiation oncology centers","sampleSize":"Full analysis set: n=319 (60 Gy: n=160; 50 Gy: n=159); 324 randomized, 331 enrolled","population":"Adults with stage IIA–IVA esophageal squamous cell carcinoma (ESCC) treated with definitive (non-surgical) intent; enrolled May 2013 – May 2017","intervention":"60 Gy in 30 fractions (2 Gy/fraction, 5 days/week) delivered via IMRT to primary tumor and regional lymph nodes, with concurrent weekly docetaxel and cisplatin (5 cycles) followed by 2 cycles of consolidation chemotherapy","comparator":"50 Gy in 25 fractions (2 Gy/fraction, 5 days/week) delivered via IMRT to primary tumor and regional lymph nodes, with the same concurrent and consolidation chemotherapy regimen","primaryOutcome":"Locoregional progression-free survival (LRPFS)","followUp":"Median follow-up: 99.5 months (approximately 8.3 years; described by authors as providing 'mature 10-year follow-up data')","fundingSource":"Not reported in the available abstract or search results"}
Key findings
After a median follow-up of 99.5 months, no statistically significant differences were observed between the 60 Gy and 50 Gy arms in locoregional progression-free survival (LRPFS), overall survival (OS), or progression-free survival (PFS). For LRPFS, the 5-year rate was 41.8% (60 Gy) vs. 43.3% (50 Gy), and the 8-year rate was 32.7% (60 Gy) vs. [value truncated in available abstract]; exact hazard ratios, confidence intervals, and p-values for the primary and secondary endpoints are not reported in the available abstract. These long-term findings are consistent with the study's previously reported short-term results, which demonstrated no improvement in locoregional control with dose escalation but documented increased radiation-related toxicity in the 60 Gy arm. Specific adverse event rates and grade ≥3 toxicity comparisons between arms at long-term follow-up are not reported in the available abstract. As an exploratory component, pretreatment biopsy specimens from enrolled patients were analyzed using NanoString GeoMx digital spatial profiling (DSP), enabling spatial transcriptomic and proteomic characterization of the tumor microenvironment; spatial biomarkers potentially associated with CRT response were identified, though specific biomarker results, effect sizes, and statistical thresholds for these exploratory findings are not reported in the available abstract. NNT and NNH cannot be calculated from the available data.
Practice implications
This trial establishes, with mature long-term follow-up (~8.3 years, median), that radiation dose escalation from 50 Gy to 60 Gy does not improve locoregional progression-free survival, overall survival, or progression-free survival in locally advanced unresectable ESCC treated with IMRT-based definitive chemoradiotherapy using a docetaxel-cisplatin regimen. These findings reinforce the prior short-term report from the same trial and are consistent with the INT 0123 trial data, which similarly failed to demonstrate a benefit from dose escalation (to 64.8 Gy) in esophageal cancer. The study population is restricted to ESCC (predominantly or exclusively East Asian, inferred), and findings should not be extrapolated to esophageal adenocarcinoma, Western populations, or other chemotherapy backbones (e.g., fluorouracil-cisplatin or carboplatin-paclitaxel). Patients with resectable disease, cervical esophageal primary, or stage IVB (metastatic) disease were not the study population. The exploratory spatial biomarker analyses (GeoMx DSP) are hypothesis-generating only; no practice-changing biomarker-directed treatment decisions are supported by the available data. Given the consistent absence of benefit with dose escalation across this trial's short- and long-term data and corroborating trials, 50 Gy remains the appropriate standard radiation dose for definitive chemoradiotherapy in locally advanced ESCC. Note: only the abstract (partially truncated) and registry-level information were available for this summary; key numeric results for OS and PFS, as well as all exploratory biomarker details, were not accessible. __LIMITATIONS__ Only the abstract (partially truncated) was available for review; specific hazard ratios, confidence intervals, and p-values for primary and secondary endpoints could not be confirmed from source text.,The trial was designed and powered for LRPFS as the primary endpoint; OS and PFS were likely secondary endpoints, and the trial may not have been independently powered for these outcomes.,The chemotherapy backbone (docetaxel-cisplatin) differs from fluorouracil-cisplatin or carboplatin-paclitaxel regimens used in many Western trials, potentially limiting generalizability.,Stage IIA–IVA is a broad and heterogeneous grouping; subgroup analyses by stage, tumor location, and baseline characteristics are not reported in the abstract.,All patients received conventionally fractionated radiotherapy; results cannot be extrapolated to hypofractionated or simultaneous integrated boost (SIB) dose-escalation strategies.,Exploratory GeoMx DSP biomarker analyses are subject to multiple testing concerns, selection bias in specimen availability, and are hypothesis-generating without prospective validation.,Funding source is not reported, precluding assessment of potential industry sponsorship bias.,Enrolled between 2013–2017; patients did not have access to immune checkpoint inhibitors, which are now being integrated into definitive CRT regimens for ESCC, limiting contemporaneous applicability.,The trial was conducted in China; generalizability to non-Asian ESCC populations (which are rare) is uncertain. __BOTTOM_LINE_CATEGORY__ confirmatory __BOTTOM_LINE__ This randomized phase 3 trial with nearly 8.5 years of median follow-up confirms that radiation dose escalation from 50 Gy to 60 Gy does not improve locoregional control, progression-free survival, or overall survival in locally advanced unresectable ESCC treated with IMRT-based definitive chemoradiotherapy, while previously demonstrating increased radiation toxicity with escalation. The data robustly support 50 Gy as the standard radiation dose for definitive chemoradiotherapy in this population. Exploratory spatial transcriptomic and proteomic biomarker findings from pretreatment biopsies are hypothesis-generating and require independent prospective validation before informing patient selection.